Key Highlights

  • Apple (NASDAQ:AAPL) reported record September-quarter Revenue of USD 114.48 billion, up 12%, but guided December-quarter gross Margin to 45% to 46% and fell about 1.9% on November 3, 2026.
  • Palantir (NASDAQ:PLTR) grew revenue 96% to about USD 2.3 billion and raised its full-year guide to about USD 8.53 billion, yet fell about 1.6% as total contract value grew only 6%.
  • Pfizer (NYSE:PFE) beat with adjusted Earnings of USD 0.87 against a published USD 0.73 and raised revenue guidance to USD 62.0 billion to USD 64.0 billion, but shares fell about 2.2%.
  • Shopify (NASDAQ:SHOP) grew revenue 32% to USD 3.74 billion but fell about 9% after gross merchandise Volume of USD 119.1 billion missed the roughly USD 120 billion expected.

Apple (NASDAQ:AAPL): The Margin Guide Was the Surprise

Apple (NASDAQ:AAPL) reported fiscal fourth-quarter results after the close on Monday, November 2, 2026, in its first report under CEO John Ternus. Revenue grew 12% to USD 114.48 billion against USD 113.39 billion expected, and diluted earnings of USD 2.10 beat the USD 1.99 consensus. iPhone revenue of USD 57.58 billion beat a USD 56.54 billion forecast. Gross margin was 47.9%, including about one point from Tariff refunds, but December-quarter guidance is 45% to 46% on rising memory costs, which management called unprecedented. Services growth was guided to 8% to 9% against 10.7% expected, and China revenue of USD 17.54 billion fell short of USD 18.58 billion. Shares barely moved on the release, fell as much as 4% during the call and closed about 1.9% lower on November 3, with other quotes from 2% to 3.8% intraday. The guided margin is a range, not a promise, and component prices can change quickly. Apple can respond with pricing, product mix or supplier terms, but each choice has trade-offs. Tariff refunds may not recur, so margin comparisons need care, and holiday-quarter Demand will decide how visible the squeeze becomes.

Palantir (NASDAQ:PLTR): Revenue Raced Ahead of Bookings

Palantir (NASDAQ:PLTR) reported third-quarter results after the close on November 2, 2026. Revenue of about USD 2.3 billion rose 96%, adjusted and GAAP earnings were both USD 0.44 against an adjusted estimate of USD 0.41, and US commercial revenue of USD 984 million, up 148%, passed US government revenue of USD 953 million for the first time. Fourth-quarter guidance of USD 2.64 billion to USD 2.65 billion compares with about USD 2.46 billion expected. The weak point was bookings: total contract value grew 6% to USD 2.9 billion, and US commercial contract value rose 11% to USD 1.5 billion. Revenue that outpaces bookings can signal slower growth ahead, and a stock priced for strong growth leaves little room for that. Palantir (NASDAQ:PLTR) rose about 1.5% after hours, fell as much as 3.6%, and closed about 1.6% lower on November 3, with another published account saying nearly 2%. Growth now depends more on US commercial customers, which brings competition from large software and cloud companies, while government contracts can be lumpy. Contract value is a leading indicator that analysts follow closely each quarter.

Pfizer (NYSE:PFE): A Beat Built on Flat Adjusted Earnings

Pfizer (NYSE:PFE) reported third-quarter results on November 3, 2026. Revenue of USD 16,583 million compares with USD 16,654 million a year earlier, essentially flat, and adjusted earnings of USD 0.87 a share were unchanged from a year earlier, though above a single published estimate of USD 0.73. The company raised 2026 revenue guidance to USD 62.0 billion to USD 64.0 billion from USD 60.5 billion to USD 62.5 billion and narrowed adjusted earnings guidance to USD 2.95 to USD 3.05. Growth excluding Comirnaty and Paxlovid was 7% operationally, with launched and acquired products up 32%, while Paxlovid fell USD 771 million, or 63%. Restructuring charges were USD 742 million in the quarter. Reported diluted earnings fell to USD 0.56 from USD 0.62, which makes Quality of Earnings a theme. Pfizer (NYSE:PFE) closed down about 2.2%, which suggests investors wanted stronger growth than a beat against a low bar. Eliquis added USD 513 million, larger than any other single product change. The midpoint of revenue guidance rose by USD 1.5 billion, but the earnings guide absorbs charges that make comparisons with last year harder.

Shopify (NASDAQ:SHOP): Volume Slipped Below the Bar

Shopify (NASDAQ:SHOP) reported third-quarter results before the open on November 3, 2026. Revenue of USD 3.74 billion grew 32%, Operating Income rose 66% to USD 568 million, and free Cash Flow was USD 816 million. Gross merchandise volume of USD 119.1 billion, up 29%, was slightly below the roughly USD 120 billion expected and slower than the 32% pace of the second quarter. One published analysis noted the stock traded at about 64 times 2027 earnings estimates before the report. Shares fell about 9%, with published intraday moves of 8.7% to 10%, leaving the stock about 22% below its October record. Fourth-quarter guidance is revenue growth in the low thirties. Shopify (NASDAQ:SHOP) also carries the costs of building artificial intelligence and agentic commerce tools, and a mix of strong cash generation with heavy Investment is a recurring debate. Competition and consumer spending are further risks. Management expects operating expenses to fall to 29% to 30% of revenue from about 32%, and investors will want evidence. A mix of strong cash generation and heavy investment keeps the debate about spending alive.

Where Things Stand

These four stocks fell after beating on at least one headline number because the market was focused on something else: margin guidance at Apple, bookings at Palantir, quality of earnings at Pfizer and volume at Shopify. Apple and Palantir both reported record growth and still slipped less than 2%, while Shopify fell about 9% on a volume miss of less than 1%, simple arithmetic on USD 119.1 billion against roughly USD 120 billion. Apple (NASDAQ:AAPL) shows that even a record print can disappoint when margin guidance falls. The common thread is that high expectations turn beats into non-events. Palantir (NASDAQ:PLTR) also shows how a stock can fall on slower bookings even as revenue nearly doubles. The next evidence is Apple's holiday-quarter iPhone demand and margin, Palantir's contract value, Pfizer's pace of non-COVID growth and Shopify's volume growth. One-day falls can reverse.